@article{d494a44f4351442b8d28ef2da58754f1,
title = "Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score",
abstract = "Aim: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. Patients & methods: Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis. Results: 82.4% (547/664) of men initially selected AS (median follow-up: 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS. Conclusion: The CCR score may aid in the identification of men who can safely defer prostate cancer treatment.",
keywords = "active surveillance, molecular score, prostate cancer, risk assessment, survival",
author = "Sanjeev Kaul and Wojno, {Kirk J.} and Steven Stone and Brent Evans and Ryan Bernhisel and Stephanie Meek and D'Anna, {Richard E.} and Jeffrey Ferguson and Jeffrey Glaser and Morgan, {Todd M.} and Jeremy Lieb and Robert Yan and Todd Cohen and Behfar Ehdaie",
note = "Funding Information: This study was conducted with Institutional Review Board oversight (Quorum, identifier 33138; MSKCC and UM internal Institutional Review Boards). This study involved anonymized, retrospective chart review and patient consent was waived. This study was supported by Myriad Genetics, Inc. and the authors from the funding institution contributed to study design, analysis and reporting. Funding Information: This work was financially supported by Myriad Genetics, Inc. B Evans, R Bernhisel, S Stone, T Cohen and S Meek were all employed by Myriad Genetics at the time of this study. S Kaul has received honoraria from and served on an advisory board and speaker{\textquoteright}s bureau for Myriad Genetics, Inc. and Intuitive Surgical; he has also received research funding from Myriad Genetics, Inc. K Wojno has served on advisory boards and/or speaker{\textquoteright}s bureaus for Myriad Genetics, Inc., Genomic Health, GenomeDx, MDxHealth and Strand Diagnositics; has receive honoraria from Strand Diagnostics; and has received research funding from Myriad Genetics, Genomic Health, Genome Dx, MDxHealth and NeoGenomics Laboratories. J Glaser has received research funding from Myriad Genetics, Inc. T Morgan has served on an advisory board for Myriad Genetics, Inc. and has received research funding from Myriad Genetics, Inc., MDxHealth and GenomeDx. R Yan has received research funding from Myriad Genetics, Inc. B Ehdaie has received honoraria and research funding from and served on an advisory board for Myriad Genetics, Inc., and received research funding from InSightec The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors acknowledge Krystal Brown and Jennifer Logan for their assistance in preparing the manuscript. Publisher Copyright: {\textcopyright} 2019 Sanjeev Kaul.",
year = "2019",
doi = "10.2217/pme-2019-0084",
language = "English",
volume = "16",
pages = "491--499",
journal = "Personalized Medicine",
issn = "1741-0541",
number = "6",
}